SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gland Pharma - Quaterly Results

29 Jan 2026 Evaluate
A fair growth of 16.50% in the revenue at Rs. 11775.13 millions was reported in the December 2025 quarter as compared to Rs. 10107.82 millions during year-ago period.Net profit showed a marginal rise at Rs. 3078.47 millions for the quarter ended December 2025, as compared to corresponding quarter of last year.The company reported a good operating profit of 4818.34 millions compared to 4562.06 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 11775.13 10107.82 16.50 32905.00 30857.96 6.63 41161.49 41674.28 -1.23
Other Income 602.07 650.64 -7.46 1975.40 1713.57 15.28 2150.75 1666.66 29.05
PBIDT 4818.34 4562.06 5.62 13528.99 12198.52 10.91 16576.93 15754.47 5.22
Interest 5.02 183.08 -97.26 119.08 193.91 -38.59 228.37 78.43 191.18
PBDT 4569.86 4378.98 4.36 13166.45 12004.61 9.68 16348.56 15676.04 4.29
Depreciation 445.30 437.67 1.74 1331.33 1261.99 5.49 1692.71 1621.07 4.42
PBT 4124.56 3941.31 4.65 11835.12 10742.62 10.17 14655.85 14054.97 4.28
TAX 1046.09 990.08 5.66 3044.12 2745.08 10.89 3758.32 3621.72 3.77
Deferred Tax -55.97 39.16 -242.93 -49.63 68.72 -172.22 91.24 246.84 -63.04
PAT 3078.47 2951.23 4.31 8791.00 7997.54 9.92 10897.53 10433.25 4.45
Equity 164.76 164.75 0.01 164.76 164.75 0.01 164.76 164.71 0.03
PBIDTM(%) 40.92 45.13 -9.34 41.12 39.53 4.01 40.27 37.80 6.53

Gland Pharma Share Price

1795.80 59.80 (3.44%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×